FDA approves ziftomenib-Komzifti for the treatment of relapsed or refractory acute myeloid leukemia with NPM1 mutations

On November 13, 2025, the Food and Drug Administration (FDA) approved ziftomenib, trade name Komzifti, produced by Kura Oncology, Inc. This approval applies to adult patients with relapsed or refractory acute myeloid leukemia (AML), specifically those with susceptible nucleophosmin 1 (NPM1) mutations, who often have no satisfactory alternative treatment options.

1. Efficacy and safety

The efficacy and safety of zitumenib were evaluated in a clinical trial calledKO-MEN-001. This was an open-label, multicenter, single-arm study enrolling 112 adults with relapsed or refractory AML. The study used next-generation sequencing or polymerase chain reaction technology to confirm the presence of NPM1 mutations, covering multiple mutation types, including type A, type B and type D mutations, as well as other mutations that may affect the cytoplasmic localization of the NPM1 protein.

The main indicators for efficacy evaluation include complete response rate (CR) and partial hematological recovery rate (CRh), as well as the duration of CR and CRh. In addition, the proportion of patients who converted from transfusion dependence to transfusion independence was also evaluated. The study results showed that the median follow-up time was 4.2 months (range, 0.1 to 41.2 months). During this time period, the overall incidence of CR and CRh was 21.4% (95% CI: 14.2% to 30.2%), and the median duration of CR and CRh was 5 months (95% CI: 1.9 to 8.1 months).

Specifically,CR rate is 17.0% (95% confidence interval: 10.5% to 25.2%), CRh rate is 4.5% (95% confidence interval: 1.5% to 10.1%). Of the 66 patients (21.2%) who were red blood cell (RBC) and/or platelet transfusion dependent at baseline, 14 (21.2%) became transfusion-free within 56 days after baseline. Of the 46 patients (26.1%) who were infusion independent at baseline, 12 (26.1%) remained infusion independent 56 days after baseline.

Some side effects were also noted in the study, especially differentiation syndrome and QTc interval prolongation, which may lead to serious health problems. In addition, zitumenib carries a warning of embryo-fetal toxicity, suggesting that women using the drug need to be particularly careful during pregnancy.

2. Recommended dosage

According to FDA approval, the recommended dose of zitumenib is 600 mg, taken orally once a day, and continued until disease progression or unacceptable toxicity occurs. Patients should strictly follow the doctor's instructions during medication and receive regular monitoring to ensure the effectiveness and safety of the treatment.

The approval of zitumenib provides a new treatment option for patients with relapsed or refractoryNPM1 mutant acute myeloid leukemia and fills the gap in clinical treatment. The drug's effectiveness and safety are supported by clinical studies, although there are potential side effects to be aware of when using it.

With the deepening of drug research, more relevant data on its efficacy and safety may be released in the future, providing more comprehensive guidance for patient treatment. When patients receive this new treatment, they should work closely with their medical team to adjust their treatment plan based on their health and response to achieve the best results.

Reference materials:https://www.drugs.com/komzifti.html